838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
References
Abatemarco, D., Perera, S., Bao, S. H., Desai, S., Assuncao, B., Tetarenko, N., . . . Mingle, E.
(2018). Training Augmented Intelligent Capabilities for Pharmacovigilance: Applying
Deep-learning Approaches to Individual Case Safety Report Processing. Pharmaceut
Med, 32(6), 391-401. doi:10.1007/s40290-018-0251-9
Aerts, H. J. W. L., Grossmann, P., Tan, Y., Oxnard, G. R., Rizvi, N., Schwartz, L. H., & Zhao, B.
(2016). Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy
in NSCLC. Sci Rep, 6, 33860. doi:10.1038/srep33860
American Society of Mechanical Engineers. (2018). Assessing Credibility of Computational
Modeling through Verification and Validation: Application to Medical Devices. In.
Arden, N. S., Fisher, A. C., Tyner, K., Yu, L. X., Lee, S. L., & Kopcha, M. (2021). Industry 4.0 for
pharmaceutical manufacturing: Preparing for the smart factories of the future. Int J
Pharm, 602, 120554. doi:10.1016/j.ijpharm.2021.120554
Athreya, A. P., Neavin, D., Carrillo-Roa, T., Skime, M., Biernacka, J., Frye, M. A., . . . Bobo, W.
V. (2019). Pharmacogenomics-Driven Prediction of Antidepressant Treatment
Outcomes: A Machine-Learning Approach With Multi-trial Replication. Clin Pharmacol
Ther, 106(4), 855-865. doi:10.1002/cpt.1482
Avram, R., Olgin, J. E., Kuhar, P., Hughes, J. W., Marcus, G. M., Pletcher, M. J., . . . Tison, G.
H. (2020). A digital biomarker of diabetes from smartphone-based vascular signals. Nat
Med, 26(10), 1576-1582. doi:10.1038/s41591-020-1010-5
Ball, R., & Dal Pan, G. (2022). "Artificial Intelligence" for Pharmacovigilance: Ready for Prime
Time? Drug Saf, 45(5), 429-438. doi:10.1007/s40264-022-01157-4
Bate, A., & Hobbiger, S. F. (2021). Artificial Intelligence, Real-World Automation and the Safety
of Medicines. Drug Saf, 44(2), 125-132. doi:10.1007/s40264-020-01001-7
Bayer, S., Clark, C., Dang, O., Aberdeen, J., Brajovic, S., Swank, K., . . . Ball, R. (2021). ADE
Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug
Labels for Pharmacovigilance. Drug Saf, 44(1), 83-94. doi:10.1007/s40264-020-00996-3
Beninger, P. (2020). Signal Management in Pharmacovigilance: A Review of Activities and
Case Studies. Clin Ther, 42(6), 1110-1129. doi:10.1016/j.clinthera.2020.03.018
Bulitta, J. B., Hope, W. W., Eakin, A. E., Guina, T., Tam, V. H., Louie, A., . . . Hoover, J. L.
(2019). Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial
Infection Model Efficacy Data To Support Translation to Humans. Antimicrob Agents
Chemother, 63(5), e02307–02318. doi:10.1128/AAC.02307-18
Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2019). Advancing Drug Discovery
via Artificial Intelligence. Trends Pharmacol Sci, 40(8), 592-604.
doi:10.1016/j.tips.2019.06.004
Cohoon, T. J., & Bhavnani, S. P. (2020). Toward precision health: applying artificial intelligence
analytics to digital health biometric datasets. Per Med, 17(4), 307-316. doi:10.2217/pme-
2019-0113
Comfort, S., Dorrell, D., Meireis, S., & Fine, J. (2018). MOdified NARanjo Causality Scale for
ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists. Drug Saf, 41(11),
1073-1085. doi:10.1007/s40264-018-0690-y
Cruz Rivera, S., Liu, X., Chan, A. W., Denniston, A. K., Calvert, M. J., & and the SPIRIT-AI and
CONSORT-AI Working Group; SPIRIT-AI and CONSORT-AI Steering Group; SPIRIT-AI
and CONSORT-AI Consensus Group. (2020). Guidelines for clinical trial protocols for
interventions involving artificial intelligence: the SPIRIT-AI extension. Nat Med, 26(9),
1351-1363. doi:10.1038/s41591-020-1037-7
Daryaee, F., & Tonge, P. J. (2019). Pharmacokinetic-pharmacodynamic models that incorporate
drug-target binding kinetics. Curr Opin Chem Biol, 50, 120-127.
doi:10.1016/j.cbpa.2019.03.008
27